Military Technology

Therefore, these patients do not have much resistance to the experiment of this new drug. After some explanation, they all accepted the new drug experimental project. Immediately, we started administering medications to these patients according to their conditions and conducted physical examinations around the clock. "

While Wu Hao was speaking, a series of relevant data information began to float above his head.

"Everyone, please see, this is the test result one day after taking the medicine, this is the test result one week later, and the following are the test results one month, two months, and three months respectively." Wu Hao introduced to the crowd.

The data shows that after one day of taking the medicine, more than 85% of the patients had a significant decrease in the gastric Helicobacter pylori carbon-13 breath test values.

After two days of taking the medicine, 98% of the patients had a very significant decrease in the gastric Helicobacter pylori carbon-13 breath test values. This is the test result after three days of taking the medicine. One hundred percent of the patients had a significant decrease in the gastric Helicobacter pylori carbon-13 breath test value, and some patients even had the gastric Helicobacter pylori carbon-13 breath test value reach normal. numerical value. "

"We immediately conducted gastric testing on the relevant patients and conducted gastric juice and tissue biopsies, and no signs of Helicobacter pylori were found."

"This is the comprehensive test result after one week of treatment. We can see that 97% of the patients have had Helicobacter pylori carbon-13 breath test values ​​in the stomach reaching normal values, and neither gastric juice nor tissue biopsy has found any. Helicobacter pylori in the stomach. And some patients’ stomachs have been very significantly cured, and many patients with conservative stomach troubles have also gained weight.”

"This is the result of our reexamination one month later. Ninety-nine percent of the patients have fully recovered, the Helicobacter pylori in the stomach has been completely cleared, and the gastric disease has been cured. Only one percent of the patients, the gastric disease has been cured." Helicobacter pylori has been significantly suppressed, but the stomach has not recovered. Two of the patients have the possibility of repeated infection."

It can be said that this new drug has a very significant and ideal therapeutic effect on Helicobacter pylori in the stomach. Compared with the currently most popular triple and quadruple therapies, it works faster and the full course of treatment is shorter. Recovery is also faster.

Moreover, we also conduct comprehensive monitoring of the patient's body, including the metabolism of our drug in the human body. In particular, many people are worried that this super phage will mutate and persist in the human body. We have carried out strict monitoring.

Data show that after entering the patient's stomach, the superphages in the drug will quickly seek out and engulf Helicobacter pylori in the stomach. The more Helicobacter pylori in the stomach, the more phagocytic divisions of this superphage. As the number of Helicobacter pylori in the stomach decreases sharply, these active superphages will begin to lose activity due to the reduction in food, and eventually die.

They will be gradually excreted from the body along with gastrointestinal metabolism. After stopping the drug, the entire metabolism time will be about forty-eight hours, and it will be completely metabolized.

We monitored all patients in the Phase I clinical trial, and all patients had superphages after taking the drug. Eighty percent of the patients metabolized it within 48 hours after stopping the drug. A small number of patients will metabolize slowly due to gastrointestinal metabolism disorders, but they will also metabolize cleanly within a week.

No superphages were detected in any patient, nor were any superphage mutations found. No case reports of hyperphage allergies or side effects have been found. Other patients with underlying diseases did not worsen their condition after taking super phages. "

Speaking of this, Wu Hao smiled at everyone in the audience and said: "At this point, our clinical trial has come to a perfect end. We have achieved very ideal results in this clinical trial. These data reports further prove that our new Drug efficacy and safety.

Immediately we applied to start the second phase of clinical trials. This time we expanded the number of patients, not only by cooperating with many domestic hospitals, but also by conducting clinical trials in hospital systems in some overseas countries.

This time, we selected a total of 23,000 patients for phase II clinical trials, including 20,000 domestic patients and 3,000 overseas patients.

And this time, we expanded the scope of testing to all patients suffering from gastric Helicobacter pylori interference, instead of only focusing on severe patients like the first phase.

Therefore, in the second phase clinical trial, we obtained a very rich and massive data information report.

The massive data information we obtained from the entire Phase II clinical trial shows that our new drug has a cure rate of 98.7% for gastric Helicobacter pylori infection. All patients participating in the Phase II clinical trial did not experience any rejection or allergic reactions while taking the drug, and there were no reports of any side effects.

All patients metabolized the drug within 48 hours to a week after stopping the drug, and no reports of gastric superphage infection treatment were reported.

It can be said that the entire Phase II clinical trial further confirmed the efficacy and safety of our new drug. "

"In order to ensure the authenticity of the entire experimental data, we have entrusted domestic and international professional medical data collection institutions to take charge of all experimental data collection results. They are responsible for this. We are not allowed to interfere in the entire process. The entire process is also conducted by relevant departments and expert groups. Supervision, there are no violations or cheating in the entire process.”

While Wu Hao was speaking, relevant report documents were simultaneously displayed above his head, proving to everyone the authenticity of what he said.

After introducing these, Wu Hao breathed a sigh of relief, and then continued: "During the entire testing process, we strictly followed the relevant international new drug clinical trial standards.

In accordance with relevant regulations, a comprehensive monitoring of the fungal infection problems that may be caused by this biopharmaceutical was carried out. We collected the excretion of feces from all patients and conducted laboratory comparisons. All superphages in their excrement have lost their activity and do not have the ability to infect. This result also further confirms the safety and environmental protection of this new drug. "

At present, we have stepped up the process of sorting out the phase II clinical trial data and started to step up the application and preparation for the larger phase III clinical trial. It is expected that the entire trial period will take about six months, and we will conduct clinical trials in more than 500 hospitals across the country, covering 100,000 patients this time.

If the experimental results go well, we will immediately start applying for the marketing of this new drug. According to the normal process, it is expected that this new drug will be launched next year.